

The lung cancer death toll remains unbelievably high. Nevertheless, improvements in survival have recently been reported thanks to early detection diagnostic programs and targeted therapies in several common forms of non-small cell lung cancer (NSCLC) driven by mutations like EGFR (Howlander N, Forjaz G, Mooradian MJ *et al.* The effect of advances in lung-cancer treatment on population mortality. *N Engl J Med* 2020). Survival benefit has been achieved principally in EGFR mutation-positive NSCLC. EGFR mutation-positive NSCLC patient frequencies are geographically uneven, being quite high in Asia and some countries in The Americas, such as Peru and Mexico, but rather lower in Western regions.

Since the first version of the *Lung Cancer* book published by AME Publishing Company in 2015, giant leaps have been attained in all fields, encompassing biological and novel imaging technique disciplines for early lung cancer diagnosis. A large part of this new edition highlights innovative thoracic surgery approaches with outstanding contributions. The Editors-in-Chief, Jianxing He, Thomas A. D'Amico, and Xiuyi Zhi, have succeeded in producing a momentous book that will satisfy the reader's needs. The book is extensive in all areas of clinical oncology and radiotherapy. It is fair to say that the book marvelously harmonizes all facets of non-small cell lung cancer. The complete final section on modern radiotherapy is well deserved and fulfills all the readers' expectations to further their learning. This book is not just another book; it will be essential and will surely be found on the desks of physicians, surgeons, biologists, and other scientists and specialists dedicated to the research and care of lung cancer patients.

AME Publishing Company's commitment to the advances in lung cancer is a great global service. The renowned international authors contributing to this *Lung Cancer* odyssey have yielded an exceptionally useful manual for students, beginners, and all types of experts, as well.

On behalf of the co-Honorary Editors-in-Chief, Nanshan Zhong, Heather A. Wakelee and myself, we would like to express our satisfaction to the authors and AME Publishing, while at the same time transmitting to the readers that they will find this second edition *Lung Cancer* book to be a thoroughly enjoyable learning experience and answer to their expectations.

Rafael Rosell, MD

*Honorary Editor-in-Chief, Lung Cancer;
Director, Cancer Biology & Precision Medicine Program,
Catalan Institute of Oncology,
Germans Trias i Pujol Research Institute and Hospital,
Associate Professor of Medicine,
Autonomous University of Barcelona (UAB),
Campus Can Ruti, 08916 Badalona, Barcelona, Spain
(Email: rrosell@iconcologia.net)*